2025-524258-32-00招募中1 期
A study of the safety, tolerability, pharmacokinetics and preliminary efficacy of TNV108 in healthy adults and patients with diabetic peripheral neuropathy
Tenvie Therapeutics Inc.1 个研究点 分布在 1 个国家目标入组 108 人开始时间: 2026年2月24日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 108
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Chief Medical Officer
Scientific
Tenvie Therapeutics Inc.
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participants2024-512939-67-00Mindstate Design Labs Inc.68
招募中
1 期
A study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 3)2023-503404-89-00Genentech Inc.45
已完成
1 期
Investigation of safety, tolerability and pharmacokinetics of multiple doses of NNC0113‑6856 in healthy participants, including a subset of healthy Japanese participants2023-503891-26-00Novo Nordisk A/S170
招募中
1 期
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma2023-504571-25-00F. Hoffmann-La Roche AG180
已完成
1 期
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid TumorsCancer2022-503080-15-00Kadmon Corporation LLC30